The independent influence of microstructural features on fracture toughness of TC21alloy with lamellar microstructure was investigated.Triple heat treatments were designed to obtain lamellar microstructures with diffe...The independent influence of microstructural features on fracture toughness of TC21alloy with lamellar microstructure was investigated.Triple heat treatments were designed to obtain lamellar microstructures with different parameters,which were characterized by OM and SEM.The size and content ofαplates were mainly determined by cooling rate from singleβphase field and solution temperature in two-phase field;while the precipitation behavior of secondaryαplatelets was dominantly controlled by aging temperature in two-phase field.The content and thickness ofαplates and the thickness of secondaryαplatelets were important microstructural features influencing the fracture toughness.Both increasing the content ofαplates and thickeningαplates(or secondaryαplatelets)could enhance the fracture toughness of TC21alloy.Based on energy consumption by the plastic zone of crack tip inαplates,a toughening mechanism for titanium alloys was proposed.展开更多
Targeted at the dynamic demands in the rapid urban construction, the planning technology strategy of the Shenzhen International Low Carbon City studies the fl exible index model based on carbon emission evaluation, an...Targeted at the dynamic demands in the rapid urban construction, the planning technology strategy of the Shenzhen International Low Carbon City studies the fl exible index model based on carbon emission evaluation, and adopts rolling development and micro-circulation construction mode to achieve quick returns with small investment. Meanwhile, it also evaluates the application of low carbon technology and gives feedback in time, so as to constantly optimize and complete the low carbon city planning. In detail, it involves industrial planning, ecological restoration, transport planning, energy resource planning, architectural design, etc., for which appropriate approaches are selected according to the principle of rolling development of unit cells and based on different requirements of different stages. The quick-response and fl exible technology system can help the low carbon city to choose an appropriate technology strategy in line with its own characteristics in the start-up stage and rapid development, thus realizing the sustainable leap-forward development and providing reference for other similar regions.展开更多
Background:In the era of immunotherapy,neoadjuvant immunochemotherapy(NAIC)for the treatment of locally advanced esophageal squamous cell carcinoma(ESCC)is used clinically but lacks of high-level clinical evidence.Thi...Background:In the era of immunotherapy,neoadjuvant immunochemotherapy(NAIC)for the treatment of locally advanced esophageal squamous cell carcinoma(ESCC)is used clinically but lacks of high-level clinical evidence.This study aimed to compare the safety and long-term efficacy of NAIC followed byminimally invasive esophagectomy(MIE)with those of neoadjuvant chemotherapy(NAC)followed by MIE.Methods:A prospective,single-center,open-label,randomized phase Ⅲ clinical trial was conducted at Henan Cancer Hospital,Zhengzhou,China.Patients were randomly assigned to receive either neoadjuvant toripalimab(240mg)plus paclitaxel(175 mg/m^(2))+cisplatin(75 mg/m^(2))(toripalimab group)or paclitaxel+cisplatin alone(chemotherapy group)every 3 weeks for 2 cycles.After surgery,the toripalimab group received toripalimab(240 mg every 3 weeks for up to 6 months).The primary endpoint was event-free survival(EFS).The pathological complete response(pCR)and overall survival(OS)were key secondary endpoints.Adverse events(AEs)and quality of life were also assessed.Results:Between May 15,2020 and August 13,2021,252 ESCC patients ranging fromT1N1-3M0 to T2-3N0-3M0were enrolled for interim analysis,with 127 in the toripalimab group and 125 in the chemotherapy group.The 1-year EFS rate was 77.9%in the toripalimab group compared to 64.3%in the chemotherapy group(hazard ratio[HR]=0.62;95%confidence interval[CI]=0.39 to 1.00;P=0.05).The 1-year OS rates were 94.1%and 83.0%in the toripalimab and chemotherapy groups,respectively(HR=0.48;95%CI=0.24 to 0.97;P=0.037).The patients in the toripalimab group had a higher pCR rate(18.6%vs.4.6%;P=0.001).The rates of postoperative Clavien-Dindo grade Ⅲb or higher morbidity were 9.8%in the toripalimab group and 6.8%in the chemotherapy group,with no significant difference observed(P=0.460).The rates of grade 3 or 4 treatment-related AEs did not differ between the two groups(12.5%versus 12.4%).Conclusions:The interim results of this ongoing trial showed that in resectable ESCC,the addition of perioperative toripalimab to NAC is safe,may improve OS and might change the standard treatment in the future.展开更多
文摘The independent influence of microstructural features on fracture toughness of TC21alloy with lamellar microstructure was investigated.Triple heat treatments were designed to obtain lamellar microstructures with different parameters,which were characterized by OM and SEM.The size and content ofαplates were mainly determined by cooling rate from singleβphase field and solution temperature in two-phase field;while the precipitation behavior of secondaryαplatelets was dominantly controlled by aging temperature in two-phase field.The content and thickness ofαplates and the thickness of secondaryαplatelets were important microstructural features influencing the fracture toughness.Both increasing the content ofαplates and thickeningαplates(or secondaryαplatelets)could enhance the fracture toughness of TC21alloy.Based on energy consumption by the plastic zone of crack tip inαplates,a toughening mechanism for titanium alloys was proposed.
文摘Targeted at the dynamic demands in the rapid urban construction, the planning technology strategy of the Shenzhen International Low Carbon City studies the fl exible index model based on carbon emission evaluation, and adopts rolling development and micro-circulation construction mode to achieve quick returns with small investment. Meanwhile, it also evaluates the application of low carbon technology and gives feedback in time, so as to constantly optimize and complete the low carbon city planning. In detail, it involves industrial planning, ecological restoration, transport planning, energy resource planning, architectural design, etc., for which appropriate approaches are selected according to the principle of rolling development of unit cells and based on different requirements of different stages. The quick-response and fl exible technology system can help the low carbon city to choose an appropriate technology strategy in line with its own characteristics in the start-up stage and rapid development, thus realizing the sustainable leap-forward development and providing reference for other similar regions.
基金Central Plains Young Top Talent,Grant/Award Number:2022Henan Province Medical Science and Technology Key Projects Coconstructed by the Ministry of Health,Grant/Award Number:SBGJ202102059+2 种基金Wu Jieping Medical Foundation,Grant/Award Number:320.6750.2020-15-1Henan Province Health Science and Technology Innovation Outstanding Young Talent Training Project,Grant/Award Number:YXKC2021029National Natural Science Foundation of China,Grant/Award Number:82002521。
文摘Background:In the era of immunotherapy,neoadjuvant immunochemotherapy(NAIC)for the treatment of locally advanced esophageal squamous cell carcinoma(ESCC)is used clinically but lacks of high-level clinical evidence.This study aimed to compare the safety and long-term efficacy of NAIC followed byminimally invasive esophagectomy(MIE)with those of neoadjuvant chemotherapy(NAC)followed by MIE.Methods:A prospective,single-center,open-label,randomized phase Ⅲ clinical trial was conducted at Henan Cancer Hospital,Zhengzhou,China.Patients were randomly assigned to receive either neoadjuvant toripalimab(240mg)plus paclitaxel(175 mg/m^(2))+cisplatin(75 mg/m^(2))(toripalimab group)or paclitaxel+cisplatin alone(chemotherapy group)every 3 weeks for 2 cycles.After surgery,the toripalimab group received toripalimab(240 mg every 3 weeks for up to 6 months).The primary endpoint was event-free survival(EFS).The pathological complete response(pCR)and overall survival(OS)were key secondary endpoints.Adverse events(AEs)and quality of life were also assessed.Results:Between May 15,2020 and August 13,2021,252 ESCC patients ranging fromT1N1-3M0 to T2-3N0-3M0were enrolled for interim analysis,with 127 in the toripalimab group and 125 in the chemotherapy group.The 1-year EFS rate was 77.9%in the toripalimab group compared to 64.3%in the chemotherapy group(hazard ratio[HR]=0.62;95%confidence interval[CI]=0.39 to 1.00;P=0.05).The 1-year OS rates were 94.1%and 83.0%in the toripalimab and chemotherapy groups,respectively(HR=0.48;95%CI=0.24 to 0.97;P=0.037).The patients in the toripalimab group had a higher pCR rate(18.6%vs.4.6%;P=0.001).The rates of postoperative Clavien-Dindo grade Ⅲb or higher morbidity were 9.8%in the toripalimab group and 6.8%in the chemotherapy group,with no significant difference observed(P=0.460).The rates of grade 3 or 4 treatment-related AEs did not differ between the two groups(12.5%versus 12.4%).Conclusions:The interim results of this ongoing trial showed that in resectable ESCC,the addition of perioperative toripalimab to NAC is safe,may improve OS and might change the standard treatment in the future.
